Why ChromaDex Stock Is Sinking Today

ChromaDex (NASDAQ: CDXC) took investors on a really wild ride on Wednesday. Shares of the global bioscience company fell as much as 26% before reversing course to eke out a small gain. But that gain was only temporary, and ChromaDex shares closed the day 4.2% lower.

The initial decline stemmed from Tuesday's decision by the U.S. District Court of Delaware to grant a summary judgment to Elysium Health, invalidating two of ChromaDex's patents for vitamin B3 supplement Niagen. ChromaDex had accused Elysium of infringing on the two patents. The rebound in the healthcare stock, though, came after ChromaDex announced plans to appeal the federal court's decision. 

Image source: Getty Images.

Continue reading

Source Fool.com